Amexdrug Corporation
Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products. It is also involved in the research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices. The company operates in two segments, Distribution and Health and Beauty Products. In addition, it engages in the distribution of p… Read more
Amexdrug Corporation - Asset Resilience Ratio
Amexdrug Corporation (AXRX) has an Asset Resilience Ratio of 65.87% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Amexdrug Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Amexdrug Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.59 Million | 65.87% |
| Total Liquid Assets | $1.59 Million | 65.87% |
Asset Resilience Insights
- Very High Liquidity: Amexdrug Corporation maintains exceptional liquid asset reserves at 65.87% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Amexdrug Corporation Industry Peers by Asset Resilience Ratio
Compare Amexdrug Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Amexdrug Corporation (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Amexdrug Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 63.66% | $1.58 Million | $2.49 Million | +14.05pp |
| 2023-12-31 | 49.61% | $1.22 Million | $2.46 Million | +19.97pp |
| 2021-12-31 | 29.64% | $852.83K | $2.88 Million | +17.57pp |
| 2020-12-31 | 12.07% | $446.60K | $3.70 Million | +11.68pp |
| 2019-12-31 | 0.39% | $9.64K | $2.47 Million | +0.04pp |
| 2018-12-31 | 0.35% | $9.64K | $2.73 Million | -0.06pp |
| 2017-12-31 | 0.41% | $9.60K | $2.31 Million | +0.26pp |
| 2016-12-31 | 0.15% | $3.60K | $2.33 Million | -0.17pp |
| 2015-12-31 | 0.32% | $5.77K | $1.80 Million | -0.23pp |
| 2014-12-31 | 0.55% | $7.65K | $1.39 Million | +0.30pp |
| 2012-12-31 | 0.25% | $5.99K | $2.41 Million | +0.12pp |
| 2011-12-31 | 0.13% | $2.11K | $1.60 Million | -0.44pp |
| 2010-12-31 | 0.57% | $7.65K | $1.34 Million | -- |